thalassemia/náusea

El enlace se guarda en el portapapeles.

Elija el tipo de clasificación

Página 1 desde 27 resultados

Combined therapy with deferiprone and desferrioxamine in thalassemia major.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE Effective and convenient iron chelation remains one of the main targets of clinical management of thalassemia major. The combined treatment with desferrioxamine and deferiprone could have an increased chelation efficacy and sometimes allow drug doses and toxicity to be reduced and the

Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Patients with thalassemia major requiring regular blood transfusions accumulate iron that is toxic to the heart, liver, and endocrine systems. The following prospective, randomized trial was carried out to determine the effectiveness, in children and young adults, of combined deferiprone (DFP) and

Efficacy and adverse effects of oral chelating therapy (deferasirox) in multi-transfused Pakistani children with β-thalassemia major.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE To determine the efficacy and adverse effects of oral chelation therapy (deferasirox) in multi-transfused β-thalassemia major patients visiting pediatric thalassemia clinic in Civil Hospital Karachi. METHODS This prospective study was conducted at pediatric thalassemia clinic of Civil

Growth hormone and adrenal response to intramuscular glucagon test and its relationship to IGF-1 production and left ventricular ejection fraction in adult B-thalassemia major patients.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

In patients with b-thalassemia major (TM), the anterior pituitary gland is particularly sensitive to free radical stresses. It has been reported that the GH deficiency (GHD) may be secondary to either pituitary or hypothalamic dysfunction. The duration of the disease, the patient's age and the

Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

UNASSIGNED β-thalassemia major patients are susceptible to Hepatitis C Virus (HCV) infection owing to life-long dependency for blood-transfusion. Moreover, this patient population is at risk of progression of liver fibrosis or development of cirrhosis as a consequence of both iron overload and HCV

Delayed hemolytic transfusion reaction with multiple alloantibody (Anti S, N, K) and a monospecific autoanti-JK(b) in intermediate β-thalassemia patient in Tabriz.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

It appears that delayed hemolytic transfusion reactions may occur several days after the administration of donor red cells is true even though they have been shown to be compatible in cross match tests by the antiglobulin technique. A specific case was observed in our center, which confirms the

Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

BACKGROUND Iron-chelating therapy with deferoxamine in patients with thalassemia major has dramatically improved the prognosis of this disease. However, the limitations of this treatment have stimulated the design of alternative orally active iron chelators. OBJECTIVE To compare the effectiveness

Jadenu® Substituting Exjade® in Iron Overloaded β-Thalassemia Major (BTM) Patients: A Preliminary Report of the Effects on the Tolerability, Serum Ferritin Level, Liver Iron Concentration and Biochemical Profiles.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

UNASSIGNED Due to the chronic nature of chelation therapy and the adverse consequences of iron overload, patient adherence to therapy is an important issue. Jadenu ® is a new oral formulation of deferasirox (Exjade ®) tablets for oral suspension. While Exjade® is a dispersible tablet that must be

Efficacy and safety of oral iron chelating agent deferiprone in beta-thalassemia and hemoglobin E-beta thalassemia.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE To assess efficacy and safety of oral iron chelating agent deferiprone (DFP) in patients with beta thalassemia and hemoglobin E-beta thalassemia. METHODS Non-randomized study. METHODS Hematology Out-Patient Department. METHODS Forty-one patients of beta thalassemia and hemoglobin E-beta

Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

BACKGROUND Osteoporosis represents the second most common cause of endocrinopathy in patients with beta thalassemia major (BTM). Some drugs proved effective to reduce vertebral and non-vertebral fracture risk. Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor

Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

BACKGROUND Iron chelation therapy is an important component in the management of patients with β-thalassemia. METHODS The study included 87 children with transfusion-dependent β-thalassemia aged 2-17 years (mean, 8.2 ± 4.1 years), 49 (56%) of whom were male. The patients received deferasirox 9-40

Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

OBJECTIVE Deferasirox (ICL670) is a novel once-daily oral iron chelator developed for the treatment of chronic iron overload from blood transfusions. This study evaluated the safety and tolerability of deferasirox in pediatric patients with transfusion-dependent beta-thalassemia major. Efficacy and

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Patients with β-thalassemia require lifelong iron chelation therapy from early childhood to prevent complications associated with transfusional iron overload. To evaluate long-term efficacy and safety of once-daily oral iron chelation with deferasirox, patients aged ≥ 2 years who completed a 1-year,

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

Nontransfusion-dependent thalassemia (NTDT) patients may develop iron overload and its associated complications despite receiving only occasional or no transfusions. The present 1-year, randomized, double-blind, placebo-controlled THALASSA (Assessment of Exjade in Nontransfusion-Dependent

Efficacy and side effects of deferiprone (L1) in thalassemia patients not compliant with desferrioxamine.

Solo los usuarios registrados pueden traducir artículos

Iniciar sesión Registrarse

We report our experience with deferiprone (L1) (DFP) in 17 thalassemic patients, followed up in one center in Lebanon, who were initially on desferrioxamine and then shifted to DFP at a dose of 50-75 mg/kg/day as the sole chelator during 1-year follow-up. All 17 patients were compliant with therapy

Únete a nuestra
página de facebook

Herbal & Natural Medicine

La base de datos de hierbas medicinales más completa respaldada por la ciencia

Funciona en 55 idiomas
Curas a base de hierbas respaldadas por la ciencia
Reconocimiento de hierbas por imagen
Mapa GPS interactivo: etiquete hierbas en la ubicación (próximamente)
Leer publicaciones científicas relacionadas con su búsqueda
Buscar hierbas medicinales por sus efectos.
Organice sus intereses y manténgase al día con las noticias de investigación, ensayos clínicos y patentes.

Escriba un síntoma o una enfermedad y lea acerca de las hierbas que podrían ayudar, escriba una hierba y vea las enfermedades y los síntomas contra los que se usa.
* Toda la información se basa en investigaciones científicas publicadas.